Inhibition of angiogenesis by erbstatin, an inhibitor of tyrosine kinase

J Antibiot (Tokyo). 1993 May;46(5):785-90. doi: 10.7164/antibiotics.46.785.

Abstract

Here we describe the inhibitory effect of erbstatin, a specific tyrosine kinase inhibitor, on in vivo angiogenesis. Inhibition of angiogenesis was determined in a bioassay system involving chorioallantoic membranes of growing chick embryos. Erbstatin produced a dose-dependent inhibitory action on embryonic angiogenesis. This inhibition occurred at as small a dose as 10 ng/egg and the ID50 value was 80 ng/egg. To analyze this inhibition, in vitro experiments involving vascular endothelial cells were also performed. Erbstatin affected the proliferation of vascular endothelial cells, one of angiogenic components. This inhibition was dose-dependent, the IC50 value being 3.6 microM. These data indicate that erbstatin-sensitive tyrosine kinase(s) is involved in angiogenic endothelial cell proliferation, and that experiments involving erbstatin will provide an important due to understand a mechanism of angiogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Division / drug effects
  • Chick Embryo
  • Dose-Response Relationship, Drug
  • Hydroquinones / pharmacology*
  • Neovascularization, Pathologic / prevention & control*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

  • Hydroquinones
  • Protein-Tyrosine Kinases
  • erbstatin